Diseases & Longevity · File 22

Colorectal cancer. The largest modifiable window in oncology — because adenoma precedes cancer by 10-15 years.

Colorectal cancer is the 3rd cause of incidence and 2nd of cancer mortality globally. Its biology offers a unique advantage: most progress from adenoma → carcinoma over 10-15 years. That makes screening the most effective oncologic secondary prevention intervention we have. USPSTF 2021 lowered start age to 45. That is a real longevity window.

Why colorectal screening is the largest opportunity in oncologic prevention

Tost colorectal cancers originate from adenomatous polyps that progress to carcinoma over 10-15 years. That gives an exceptionally wide window to detect and resect polyps before they transform — something other organ oncology rarely offers. Colonoscopy screening identifies and resects polyps in the same procedure. It's secondary prevention with a direct switch.

USPSTF 2021 lowered screening start age to 45 (previously 50) — responding to documented increase of early-onset colorectal cancer (EOCRC) in adults 40-49 in US, Europe, and Latin America. Options: colonoscopy every 10 years, annual FIT (fecal immunochemical test), sigmoidoscopy + FIT, or occult blood. Choice is individualized — efficacy × adherence.

Adenoma precedes colorectal carcinoma by 10-15 years. Resecting it interrupts cancer before it exists — that window is not offered by other oncology.
New cases · 2022 global

The global weight, in numbers

Quantitative colorectal cancer data come from GLOBOCAN, USPSTF, ACS, and longitudinal meta-analyses. They confirm the screening opportunity.

  • Incidence and mortality

    3ra incidencia / 2da mortalidad

    GLOBOCAN 2022: ~1.9 million new cases and ~930k annual deaths globally. It's the 3rd cancer in incidence (after breast and lung) and 2nd in mortality (after lung).
    — GLOBOCAN 2022

  • Early-onset CRC (EOCRC)

    Aumento documentado

    Early-onset colorectal cancer (<50) has increased in the last 30 years in US, Europe, and Latin America. That's why USPSTF 2021 lowered screening age to 45.
    — Siegel et al., CA Cancer J Clin 2024

  • Mortality reduction with screening

    Sostenida y robusta

    Multiple trials (NORCCAP, Nordic, UK Flexisig) show sustained 10-15 year incidence and mortality reduction with colonoscopy or sigmoidoscopy + FIT screening vs no screening.
    — Lin et al., JAMA 2021

  • Lynch and hereditary forms

    ~3-5% de casos

    Lynch syndrome (MMR genes: MLH1, MSH2, MSH6, PMS2) explains 3-5% of colorectal cancers. Suspect in families with early colorectal cancer, endometrial cancer, or multiple Lynch-associated cancers.
    — Lynch et al., Familial Cancer 2019

Chap. 03 · Cardiometabolic-microbiota

Modifiable risk factors and trajectory

Beyond screening, there are modifiable factors that reduce incidence. Longevity medicine operates on these biological axes shared with the cardiometabolic cluster.

  • Cardiometabolic cluster

    Obesidad + DM2 + inflamación

    Central obesity, T2D, and hyperinsulinemia increase colorectal cancer risk — mechanism is IGF-1/insulin + chronic inflammation. Intervention on the cluster is also oncologic prevention.
    — Lauby-Secretan, NEJM 2016

  • Processed meat and alcohol

    IARC grupo 1 / grupo 1

    IARC classifies processed meat as group 1 carcinogen for colorectal cancer. Alcohol also group 1 with dose-dependent association. High red meat consumption associated with increased risk (group 2A).
    — IARC Monograph 2018; Bouvard, Lancet Oncol 2015

  • Colorectal microbiota

    Diana emergente

    Microbial dysbiosis — particularly Fusobacterium nucleatum and pro-inflammatory gene enrichment — is associated with higher colorectal cancer risk. It's an active research target but without specific approved intervention yet.
    — Wong & Yu, Nat Rev Gastroenterol 2019

  • Aspirin as prevention

    Evidencia mixta

    Low-dose aspirin reduces colorectal cancer incidence at 10+ years — but benefit must be balanced with bleeding risk. USPSTF 2022 withdrew routine aspirin recommendation for CV/CRC prevention in >60. Individualized decision with treating physician.
    — USPSTF 2022; Rothwell et al., Lancet 2010

What we don't offer — and what we do

Wellness Care does not perform colonoscopy or oncologic surgery. Colonoscopy, polypectomy, biopsy, oncologic surgery, chemotherapy, radiotherapy, and immunotherapy are the responsibility of gastroenterologist, oncologic surgeon, and oncologist. What we do is what the conventional system rarely integrates: structured risk evaluation, indication of appropriate screening, and management of the shared cardiometabolic cluster.

We evaluate patients with: 45+ years without up-to-date screening, family history of colorectal cancer (including suspected Lynch or FAP), significant cardiometabolic cluster, high exposure to dietary risk factors, family EOCRC, or already-treated colorectal cancer patients in remission wanting to optimize secondary prevention. Evaluation orients screening indication and addresses modifiable factors. Coordination with gastroenterology and oncology when indicated.

Colorectal screening is the oncologic secondary prevention with most evidence. Not doing it at 45+ is not optional — it's losing the only intervention with directly demonstrated effect.
How we measure it

How colorectal risk is evaluated
at Wellness Care

Screening appropriate to individual risk + cluster modifiable factors + microbiota when applicable + gastroenterology coordination. That integration changes trajectory.

Advanced biomarkers

21 specialized panels across 8 clinical categories — biological age, inflammaging, metabolic profile, functional hormonal, microbiota. The quantitative layer.

Explore →

Functional medicine

Shared root causes — mitochondrial dysfunction, inflammaging, neuroendocrine dysregulation — before organ pathology.

Explore →

Bioregulatory medicine

Autonomic regulation, HRV, stress response. The functional trajectory that precedes clinical diagnosis.

Explore →

The Longevity Program

How this assessment integrates into the full program — from initial valuation to individualized protocol design under medical judgment.

Explore →
Featured evidence

Key evidence supporting this approach

Four publications structuring the modern conversation — USPSTF 2021, EOCRC, IARC, and obesity/cancer.

«La USPSTF actualizó la recomendación de cribado de cáncer colorrectal a partir de los 45 años — respondiendo al aumento documentado de casos en adultos jóvenes.»
JAMA · 2021
USPSTF, JAMA 2021
Edad de inicio 45 años
«El cáncer colorrectal de inicio temprano (<50 años) ha aumentado de forma documentada en las últimas tres décadas en EE.UU., Europa y América Latina.»
CA Cancer J Clin · 2024
Siegel et al., CA Cancer J Clin 2024
EOCRC en aumento
«IARC clasifica carne procesada como cancerígeno grupo 1 para cáncer colorrectal — y carne roja como grupo 2A con asociación dosis-dependiente.»
Lancet Oncol · 2015
Bouvard et al., Lancet Oncol 2015
IARC · carne procesada

Frequently asked questions about colorectal cancer

The most recurrent questions about colorectal cancer — screening, start age, FIT vs colonoscopy, dietary factors, and why longevity medicine complements gastroenterology.

01

At what age should I start screening?

USPSTF 2021 and ACS recommend starting screening at 45 in average risk (previously 50).

If there's:

· Family history of early colorectal cancer
· Suspected Lynch / FAP
· Inflammatory bowel disease

Screening starts earlier and more frequently.

Final decision, modality, and intervals are defined by the gastroenterologist per your individual profile.

02

Colonoscopy or FIT? Which is better?

Colonoscopy — gold standard:

· Directly visualizes all mucosa
· Allows polypectomy in same procedure
· Interval: every 10 years in average risk without polyps

FIT (fecal immunochemical test):

· Non-invasive
· Annual
· Reasonable cancer sensitivity, lower for flat polyps

What matters is adherence: the best screening is the one done.

If colonoscopy isn't viable, annual FIT is valid alternative — always with gastroenterology follow-up.

03

What dietary factors really matter?

Best-evidence factors:

Reduce:

· Processed meat (IARC group 1)
· High red meat consumption (group 2A)
· Alcohol (dose-dependent association)

Increase:

· Dietary fiber — whole grains, legumes, fruits, vegetables
· Calcium and dairy — modest protective effect

Maintain:

· Healthy weight
· Regular physical activity

Low-dose aspirin has mixed evidence and requires individualized decision with treating physician.

04

When to suspect Lynch syndrome?

Suspect Lynch if:

· Colorectal or endometrial cancer before age 50
· Multiple Lynch-associated cancers in family:
  · Colorectal
  · Endometrium
  · Ovary
  · Gastric
  · Urothelial
  · Small bowel
· Colorectal cancer with microsatellite instability (MSI-H) or MMR protein loss in immunohistochemistry

Genetic study orients confirmation. Lynch families require intensified screening from early ages.

05

When should I consult?

A structured assessment is worthwhile if:

· You're 45+ without up-to-date screening
· Family history of early colorectal cancer
· Rectal bleeding / persistent bowel habit change / unexplained weight loss
· Suspected Lynch / FAP
· Family EOCRC
· Significant cardiometabolic cluster with dietary risk factors

The assessment orients screening and addresses modifiable factors. Colonoscopy and diagnosis belong to gastroenterology.

10-15 years of modifiable window

Colorectal cancer offers the largest modifiable window in all oncology — because adenoma precedes carcinoma by 10-15 years.

Screen at 45+, address the cardiometabolic cluster and dietary factors, identify Lynch / family EOCRC, and coordinate with gastroenterology — that really changes incidence and mortality.

Are you 45+ or have family history?

Book a colorectal risk and longevity assessment

We evaluate detailed clinical history, family history (Lynch, FAP), modifiable risk factors (diet, alcohol, smoking, obesity, inflammation), colonoscopy or FIT indication per USPSTF/ACS criteria, colorectal microbiota when applicable, and cardiometabolic cluster comorbidities. Does not replace gastroenterology / oncology — complements them.

Book colorectal risk assessment